Australia's CSL set for worst week in 2 months on delaying spin-off
** CSL CSL.AX slips 15.5% to A$179.77 so far this week; set for biggest weekly drop since week ended August 22 ** Biotech major no longer targetting spin-off of its vaccine division, Seqirus, in FY26 due to heightened volatility in U.S. influenza vaccine market ** Says demerger will resume when market conditions can support maximisation of shareholder value ** CSL last down 0.1%, takes YTD losses to 36.2% (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.singhchundawat@thomsonreuters.com))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX